From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Hotdogs and motorways: The ripples created by Denmark's Ozempic and Wegovy boom
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
STAT7h
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
manilatimes15h
Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
CardCash.com, Giftify's secondary gift card exchange platform, provides consumers with an innovative approach to reduce rising out-of-pocket expenses for increasingly popular GLP-1 medications. The ...
‘We made 434pc on one stock – now we’re hunting for the next Ozempic’
Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.
Lexaria Bioscience Corp.: Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...
STAT19h
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...